Intestinal defensin secretion in infancy is associated with the emergence of sensitization and atopic dermatitis

Clinical and Experimental Allergy

Volumn 42, Issue 3, 2012, Pages 405-411

  Savilahti, E M ^a   Kukkonen, A K ^a   Haahtela, T ^a   Tuure, T ^b   Kuitunen, M ^a   Savilahti, E ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b VALIO LTD   (Finland)

Author keywords

Allergy; Atopic dermatitis; Defensins; Innate immunity; Symbiotic

Indexed keywords

BETA DEFENSIN 2; DEFENSIN; HUMAN NEUTROPHIL PEPTIDE 1-3; PEPTIDE; PLACEBO; SYNBIOTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; ATOPIC DERMATITIS; ATOPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; INFANCY; INFANT; INNATE IMMUNITY; LACTIC ACID BACTERIUM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SENSITIZATION;

BETA-DEFENSINS; CHILD, PRESCHOOL; DEFENSINS; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FECES; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INFANT; INTESTINAL MUCOSA; PREGNANCY; SYNBIOTICS;

EID: 84857445043     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03904.x     Document Type: Article

References (35)

1. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009; 30:131-41.
2. Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest 1989; 84:553-61.
3. Rohrl J, Yang D, Oppenheim JJ, Hehlgans T. Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. J Immunol 2010; 184:6688-94.
4. Funderburg N, Lederman MM, Feng Z et al. Human-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 2007; 104:18631-5.
5. Lillard JW, Jr, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci USA 1999; 96:651-6.
6. Doss M, White MR, Tecle T, Hartshorn KL. Human defensins and LL-37 in mucosal immunity. J Leukoc Biol 2010; 87:79-92.
7. Wehkamp J, Salzman NH, Porter E et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 2005; 102:18129-34.
8. Peyrin-Biroulet L, Beisner J, Wang G et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 2010; 107:8772-7.
9. Langhorst J, Junge A, Rueffer A et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104:404-10.
10. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347:1151-60.
11. Tulic MK, Hodder M, Forsberg A et al. Differences in innate immune function between allergic and nonallergic children: new insights into immune ontogeny. J Allergy Clin Immunol 2010; 127:470-8.e1.
12. Roduit C, Wohlgensinger J, Frei R et al. Prenatal animal contact and gene expression of innate immunity receptors at birth are associated with atopic dermatitis. J Allergy Clin Immunol 2011; 127:179, 185.e1.
13. Salzman NH, Hung K, Haribhai D et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010; 11:76-83.
14. Wehkamp J, Harder J, Wehkamp K et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004; 72:5750-8.
15. Schlee M, Harder J, Koten B, Stange EF, Wehkamp J, Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 2008; 151:528-35.
16. Mondel M, Schroeder BO, Zimmermann K et al. Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and faecal excretion in humans. Mucosal Immunol 2009; 2:166-72.
17. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol 2008; 121:116, 121.e11.
18. Ozdemir O. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin Exp Immunol 2010; 160:295-304.
19. Kukkonen K, Savilahti E, Haahtela T et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2007; 119:192-8.
20. Kuitunen M, Kukkonen K, Juntunen-Backman K et al. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. J Allergy Clin Immunol 2009; 123:335-41.
21. Williams HC, Burney PG, Hay RJ et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994; 131:383-96.
22. Bruijnzeel-Koomen C, Ortolani C, Aas K et al. Adverse reactions to food. European Academy of Allergology and Clinical Immunology Subcommittee. Allergy 1995; 50:623-35.
23. International Rhinitis managing Working Group. International consensus report on the diagnosis and management of rhinitis. Allergy 1994; 49:1-34.
24. The European Academy of Allergology and Clinical Immunology. Position paper: allergen standardization and skin tests. Allergy 1993; 48:48-82.
25. Kukkonen K, Kuitunen M, Haahtela T, Korpela R, Poussa T, Savilahti E. High intestinal IgA associates with reduced risk of IgE-associated allergic diseases. Pediatr Allergy Immunol 2010; 21:67-73.
26. Vercelli D. Mechanisms of the hygiene hypothesis-molecular and otherwise. Curr Opin Immunol 2006; 18:733-7.
27. Simpson A, John SL, Jury F et al. Endotoxin exposure, CD14, and allergic disease: an interaction between genes and the environment. Am J Respir Crit Care Med 2006; 174:386-92.
28. Campeotto F, Baldassarre M, Laforgia N et al. Faecal expression of human beta-defensin-2 following birth. Neonatology 2010; 98:365-9.
29. Ganz T, Selsted ME, Szklarek D et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985; 76:1427-35.
30. Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol 1997; 159:1739-45.
31. Pohjavuori E, Viljanen M, Korpela R et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. J Allergy Clin Immunol 2004; 114:131-6.
32. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001; 108:516-20.
33. Sepp E, Julge K, Mikelsaar M, Bjorksten B. Intestinal microbiota and immunoglobulin E responses in 5-year-old Estonian children. Clin Exp Allergy 2005; 35:1141-6.
34. Suzuki S, Shimojo N, Tajiri Y, Kumemura M, Kohno Y. Differences in the composition of intestinal Bifidobacterium species and the development of allergic diseases in infants in rural Japan. Clin Exp Allergy 2007; 37:506-11.
35. Gore C, Munro K, Lay C et al. Bifidobacterium pseudocatenulatum is associated with atopic eczema: a nested case-control study investigating the faecal microbiota of infants. J Allergy Clin Immunol 2008; 121:135-40.